Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study

医学 贝伐单抗 彭布罗利珠单抗 肿瘤科 化疗 危险系数 实体瘤疗效评价标准 内科学 外科 癌症 进行性疾病 免疫疗法 置信区间
作者
D. Lorusso,Nicoletta Colombo,Coraline Dubot,M.V. Cáceres,Kazuki Hasegawa,Ronnie Shapira‐Frommer,Pamela Salman,Eduardo Yáñez,Mahmut Gümüş,Mivael Olivera,Vanessa Samouëlian,Vincent Castonguay,A. Arkhipov,Ka Wan Li,S. Toker,Çağla Tekin,Krishnansu S. Tewari,B.J. Monk
出处
期刊:Annals of Oncology [Elsevier BV]
被引量:6
标识
DOI:10.1016/j.annonc.2024.10.002
摘要

HIGHLIGHTS•This exploratory analysis of KEYNOTE-826 examined treatment outcomes in patient subgroups defined by bevacizumab (beva) use•Pembrolizumab+chemotherapy improved progression-free survival and overall survival vs placebo+chemotherapy in all subgroups•The safety profile of pembrolizumab+chemotherapy±beva was manageable•Results support use of pembrolizumab+chemotherapy±beva for persistent, recurrent, or metastatic cervical cancerABSTRACTBackgroundIn KEYNOTE-826 (NCT03635567), pembrolizumab plus chemotherapy (± bevacizumab) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with persistent, recurrent, or metastatic cervical cancer. This exploratory analysis examined outcomes in patient subgroups defined by bevacizumab use.Patients and methodsEligible adult patients had persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix not previously treated with chemotherapy and not amenable to curative treatment; measurable disease per RECIST v1.1; and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1:1 to pembrolizumab 200 mg every 3 weeks or placebo for up to 35 cycles plus chemotherapy (± bevacizumab 15 mg/kg). Dual primary endpoints were OS and PFS per RECIST v1.1 by investigator assessment. Outcomes were assessed in subgroups defined by bevacizumab use. Hazard ratios (HRs) and 95% CIs were based on a stratified Cox regression model.Results617 patients were randomized (pembrolizumab arm, n=308 [63.6% with bevacizumab]; placebo arm, n=309 [62.5% with bevacizumab]). The most common reason for bevacizumab exclusion was medical contraindication (75.9%). Among patients who received bevacizumab, HRs (95% CIs) for PFS favored the pembrolizumab arm in the PD-L1 combined positive score (CPS) ≥1 (0.56 [0.43−0.73]) and all-comer (0.57 [0.45−0.73]) populations; OS results were 0.60 (0.45−0.79) and 0.61 (0.47−0.80), respectively. Among patients who did not receive bevacizumab, HRs (95% CIs) for PFS also favored the pembrolizumab arm in the PD-L1 CPS≥1 (0.61 [0.44−0.85]) and all-comer (0.69 [0.50−0.94]) populations; OS results were 0.61 (0.44−0.85) and 0.67 (0.49−0.91), respectively. Among patients who received bevacizumab, grade ≥3 treatment-related adverse events occurred in 74.0% of patients in the pembrolizumab arm and 66.8% in the placebo arm.ConclusionPembrolizumab plus chemotherapy prolonged PFS and OS and had manageable safety compared with placebo plus chemotherapy in patient subgroups defined by bevacizumab use.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
glomming完成签到 ,获得积分10
3秒前
wanci应助南瓜气气采纳,获得30
5秒前
晓晓发布了新的文献求助10
5秒前
英姑应助梨理栗采纳,获得10
6秒前
东方红发布了新的文献求助10
6秒前
ah爱科研完成签到,获得积分10
7秒前
7秒前
9秒前
若梦易燃发布了新的文献求助10
9秒前
思源应助全若之采纳,获得10
9秒前
10秒前
11秒前
积极的笑柳完成签到,获得积分10
12秒前
JUNE发布了新的文献求助10
12秒前
小鱼发布了新的文献求助10
15秒前
小仙女212发布了新的文献求助10
16秒前
16秒前
可爱得喵喵叫的中华卷柏完成签到,获得积分10
17秒前
17秒前
tianmengkui完成签到,获得积分10
19秒前
轻松的万天完成签到 ,获得积分10
20秒前
x夏天完成签到 ,获得积分10
20秒前
晓晓完成签到,获得积分10
20秒前
繁荣的代秋完成签到 ,获得积分10
21秒前
马小跳完成签到,获得积分20
21秒前
22秒前
22秒前
23秒前
Infinit完成签到,获得积分10
24秒前
24秒前
27秒前
量子星尘发布了新的文献求助10
28秒前
y924758705发布了新的文献求助10
28秒前
29秒前
32秒前
瘦瘦天奇发布了新的文献求助10
32秒前
莉丽发布了新的文献求助10
34秒前
37秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073